비교리스트

 카트 문의
시장보고서
상품코드
1514147

세계의 항균제 시장

Antibacterial Drugs
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 244 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항균제의 시장은 2030년까지 586억 달러에 달할 전망입니다.

2023년에 449억 달러로 평가된 항균제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 3.9%로 성장할 전망이며 2030년에는 586억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 B-락탐 약물 클래스별은 복합 연간 성장률(CAGR) 4.1%로 성장을 지속하고, 분석 기간 종료 시에는 354억 달러에 달할 것으로 예측됩니다. 매크로 라이드 약물 등급별 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 4.4%로 추정됩니다.

미국 시장은 122억 달러로 추정되며 중국은 복합 연간 성장률(CAGR) 6.5%로 성장할 것으로 예측됩니다.

미국 항균제 시장은 2023년 122억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 121억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR) 6.5%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 2.0%와 3.2%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 2.6%로 성장할 것으로 예측됩니다.

항균제 - 주요 동향 및 촉진요인

일반적으로 항생제로 알려진 항균제는 박테리아 감염의 치료에 필수적이며 현대 의학의 핵심입니다. 이러한 약제는 그 작용기전에 의해 세균을 사멸시키는(살균성) 또는 세균의 증식을 억제하는(정균성)의 어느쪽이든으로 작용합니다. 항균제는 페니실린계, 세팔로스포린계, 테트라사이클린계, 마크로라이드계, 플루오로퀴놀론계, 아미노글리코시드계 등 여러 범주로 분류되며, 각각은 특정 유형의 박테리아를 표적으로 하고 있습니다. 예를 들어, 페니실린 시스템과 세팔로스포린 시스템은 박테리아의 세포벽 합성을 억제하고, 테트라사이클린 시스템은 단백질 합성을 억제합니다. 이 약물은 가벼운 피부 감염과 호흡기 감염에서 패혈증, 세균성 수막염, 결핵과 같은 심각한 증상에 이르기까지 다양한 세균 감염의 치료에 사용됩니다. 항생제의 발견과 광범위한 사용은 박테리아 감염과 관련된 이환율과 사망률을 극적으로 감소시켜 의학 역사상 가장 중요한 진보 중 하나가되었습니다.

항균제 시장에서 중요한 동향은 박테리아가 항생제의 효과를 견디는 메커니즘을 진화시키는 항생제 내성 문제 증가입니다. 이 현상은 여러 항생제에 내성을 가지며 공중 보건에 심각한 위협을 초래하는 슈퍼 버그의 시작으로 이어집니다. 세계보건기구(WHO)는 항생제 내성을 세계 건강 위협의 최상위에 꼽고 있습니다. 이 위기에 대응하기 위해 새로운 항생제와 대체 요법의 개발에 중점을 둡니다. 세균에 특이적으로 감염하여 죽이는 바이러스인 박테리오파지와 세균막을 파괴하는 항균 펩타이드의 연구가 진행되고 있습니다. 또한 내성균의 주된 원인이 되는 과잉 사용과 오용을 줄이기 위한 스튜어드십 프로그램을 통해 항생제의 책임 있는 사용을 촉진하는 노력도 이루어지고 있습니다. 이 프로그램은 적절한 항생제 사용의 중요성과 내성 박테리아의 잠재적 영향에 대한 건강 관리 전문가와 일반 시민을 교육하는 데 중점을 둡니다. 제약회사와 연구기관은 신규 항균제의 발견이나 기존 약의 내성주 대책에의 재이용을 목적으로 한 혁신적인 연구에 다액의 투자를 실시하고 있어 유효한 치료법의 확보에 노력하고 있습니다.

항균제 시장의 성장은 창약 기술의 진보, 세균 감염의 유행 증가, 항생제 내성에 대한 의식 증가 등 여러 요인에 의해 견인되고 있습니다. 높은 처리량 스크리닝, 유전체학, 바이오인포매틱스 등의 기술 진보에 의해 신규 항생제의 발견이 가속화되고, 내성균 메커니즘의 해명이 진행되고 있습니다. 이러한 기술을 통해 연구자는 새로운 창약 표적을 확인하고 더 효과적인 항균제를 개발할 수 있습니다. 인구 고령화, 입원 증가, 만성 질환 이환율 증가 등의 요인에 의해 악화되는 세균 감염의 유병률 증가는 효과적인 항균 치료제에 대한 수요를 계속 견인하고 있습니다. 게다가 공중보건 활동과 교육 캠페인은 항생제 내성의 위험성에 대한 인식을 높이고, 보다 효과적인 새로운 치료제에 대한 수요를 높이고 있습니다. 박테리아 감염과 내성 패턴을 파악하기 위한 신속 진단 도구 시장 개척도 보다 효과적이고 효과적인 치료를 가능하게 하기 위해 시장 성장을 가속하고 있습니다. 또한 정부 및 비정부 조직의 연구개발 활동에 대한 자금 지원과 신규 항생제의 신속한 심사 과정과 같은 규제 우대 조치가 시장 혁신을 촉진하고 있습니다. 전반적으로 이러한 요인들이 결합되어 항균제 시장의 지속적인 성장과 기술 혁신이 촉진되고 박테리아 감염과의 싸움에서 중요한 의약품의 지속적인 효능이 보장됩니다.

조사 대상 기업 예(주목 124사)

  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global Antibacterial Drugs Market to Reach US$58.6 Billion by 2030

The global market for Antibacterial Drugs estimated at US$44.9 Billion in the year 2023, is expected to reach US$58.6 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2023-2030. B-lactams Drug Class, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. Growth in the Macrolides Drug Class segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.2 Billion While China is Forecast to Grow at 6.5% CAGR

The Antibacterial Drugs market in the U.S. is estimated at US$12.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12.1 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Antibacterial Drugs - Key Trends and Drivers

Antibacterial drugs, commonly known as antibiotics, are essential in the treatment of bacterial infections and are a cornerstone of modern medicine. These drugs work by either killing bacteria (bactericidal) or inhibiting their growth (bacteriostatic), depending on their mechanism of action. Antibacterial drugs are classified into several categories, including penicillins, cephalosporins, tetracyclines, macrolides, fluoroquinolones, and aminoglycosides, each targeting specific types of bacteria. For example, penicillins and cephalosporins disrupt bacterial cell wall synthesis, while tetracyclines inhibit protein synthesis. These drugs are used to treat a wide range of bacterial infections, from minor skin infections and respiratory tract infections to more severe conditions such as sepsis, bacterial meningitis, and tuberculosis. The discovery and widespread use of antibiotics have dramatically reduced the morbidity and mortality associated with bacterial infections, representing one of the most significant advancements in medical history.

A significant trend in the antibacterial drugs market is the increasing problem of antibiotic resistance, where bacteria evolve mechanisms to withstand the effects of antibiotics. This phenomenon has led to the rise of "superbugs" which are resistant to multiple antibiotics and pose a severe threat to public health. The World Health Organization (WHO) has identified antibiotic resistance as one of the top global health threats. In response to this crisis, there is a growing emphasis on developing new antibiotics and alternative therapies. Research is being directed towards bacteriophages, viruses that specifically infect and kill bacteria, and antimicrobial peptides, which can disrupt bacterial membranes. Efforts are also being made to promote the responsible use of antibiotics through stewardship programs aimed at reducing overuse and misuse, which are primary drivers of resistance. These programs focus on educating healthcare professionals and the public about the importance of appropriate antibiotic use and the potential consequences of resistance. Pharmaceutical companies and research institutions are investing heavily in innovative research to discover novel antibacterial agents and repurpose existing drugs to combat resistant strains, ensuring that effective treatments remain available.

The growth in the antibacterial drugs market is driven by several factors, including technological advancements in drug discovery, the increasing prevalence of bacterial infections, and the rising awareness of antibiotic resistance. Technological advancements, such as high-throughput screening, genomics, and bioinformatics, have accelerated the discovery of new antibiotics and enhanced the understanding of bacterial resistance mechanisms. These technologies enable researchers to identify novel drug targets and develop more effective antibacterial agents. The growing prevalence of bacterial infections, exacerbated by factors such as aging populations, increased hospitalizations, and the rising incidence of chronic diseases, continues to drive demand for effective antibacterial treatments. Additionally, public health initiatives and educational campaigns have raised awareness about the dangers of antibiotic resistance, leading to increased demand for new and more effective antibacterial drugs. The development of rapid diagnostic tools to identify bacterial infections and resistance patterns is also propelling market growth, as these tools enable more targeted and effective treatments. Furthermore, the support from government and non-government organizations in funding research and development activities, as well as regulatory incentives such as expedited review processes for new antibiotics, is fostering innovation in the market. Overall, the combination of these factors is driving sustained growth and innovation in the antibacterial drugs market, ensuring the continued effectiveness of these critical medicines in the fight against bacterial infections.

Select Competitors (Total 124 Featured) -

  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Antibacterial Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Bacterial Infections Expands Addressable Market Opportunity for Antibacterial Drugs
    • Advances in Drug Discovery Technologies Propel Growth in the Antibacterial Drugs Market
    • Increasing Antibiotic Resistance Throws the Spotlight on New Drug Development
    • Development of Novel Antibiotics Strengthens Business Case for Innovative Treatments
    • High-Throughput Screening Techniques Accelerate Identification of New Antibacterial Compounds
    • Genomic Research Spurs Growth by Uncovering New Drug Targets
    • Integration of Bioinformatics in Drug Development Expands Market Potential
    • Public Health Initiatives Drive Adoption of Responsible Antibiotic Use Programs
    • Rising Awareness of Antibiotic Resistance Generates Demand for New Treatments
    • Increasing Prevalence of Hospital-Acquired Infections Sustains Market Growth
    • Expansion of Rapid Diagnostic Tools Enhances Market for Targeted Antibacterial Therapies
    • Growth in Aging Population Expands Need for Effective Antibacterial Drugs
    • Advances in Bacteriophage Therapy Generate Opportunities for Alternative Treatments
    • Growing Use of Antimicrobial Peptides Propels Market Growth
    • Evolving Healthcare Infrastructure in Emerging Markets Expands Market Reach for Antibacterial Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibacterial Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for B-lactams by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for B-lactams by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for B-lactams by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tetracyclines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tetracyclines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tetracyclines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Antibacterial Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Antibacterial Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Antibacterial Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Antibacterial Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제